Novel peptide linkers for highly potent antibody-auristatin conjugate

Bioconjugate Chemistry

Volumn 19, Issue 10, 2008, Pages 1960-1963

  Doronina, Svetlana O ^a   Bovee, Tim D ^a   Meyer, David W ^a   Miyamoto, Jamie B ^a   Anderson, Martha E ^a   Morris Tilden, Carol A ^a   Senter, Peter D ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; ENZYME ACTIVITY; PEPTIDES;

AMINO-ACIDS; ANTIBODY-DRUG CONJUGATES; ANTIMITOTIC AGENTS; DI-PEPTIDES; N-TERMINALS; NOVEL PEPTIDES; PEPTIDE LINKERS; TERMINAL RESIDUES; THERAPEUTIC INDEX; TUMOUR CELLS;

AMINO ACIDS;

ANTIBODY CONJUGATE; ANTIMITOTIC AGENT; AURISTATIN F; MONOCLONAL ANTIBODY VALYLCITRULLINE 4 AMINOBENZYLCARBAMATE MONOMETHYLAURISTATIN F CONJUGATE; MONOMETHYLAURISTATIN F; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG UPTAKE; HUMAN; HUMAN CELL; IC 50; KIDNEY CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR XENOGRAFT;

EID: 55249097877     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc800289a     Document Type: Article

References (19)

1. Carter, P. J., and Senter, P. D. (2008) Antibody-drug conjugates for cancer therapy. Cancer J. 14, 154-69.
2. Chari, R. V. (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 41, 98-107.
3. Beeram, M., Krop, I., Modi, S., Tolcher, A., Rabbee, N., Girish, S., Tibbitts, J., Holden, S., Lutzker, S., and Burris, H. (2007) A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC). J. Clin. Oncol. 25, Abstract 1042.
4. Krop, I. E., Beeram, M., Modi, S., Rabbee, N., Girish, S., Tibbitts, J., Holden, S. N., Lutzker, S. G., and Burris, H. A. (2007) A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer, In 30th Annual San Antonio Breast Cancer Symposium, Abstract 310.
5. Younes, A., Forero-Torres, A., Bartlett, N., Leonard, J. P., Rege, B., Kennedy, D. A., Lorenz, J., and Sievers, E. L. (2007) A novel antibody-drug conjugate, SGN-35, (anti-CD30-auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma, preliminary results of a phase I tolerability study, In 7th International Symposium on Hodgkin Lymphoma.
6. Younes, A., Forero-Torres, A., Bartlett, N. L., Leonard, J. P., Rege, B., Kennedy, D. A., Lorenz, J. M., and Sievers, E. L. (2008) Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory hodgkin lymphoma. Am. Soc. Clin. Oncol.
7. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. L., and Senter, P. D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778-84.
8. Sanderson, R. J., Hering, M. A., James, S. F., Sun, M. M., Doronina, S. O., Siadak, A. W., Senter, P. D., and Wahl, A. F. (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res. 11, 843-52.
9. Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., Law, C. L., Doronina, S. O., Siegall, C. B., Senter, P. D., and Wahl, A. F. (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102, 1458-65.
10. Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., Wahl, A. F., and Senter, P. D. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjugate Chem. 17, 114-24.
11. Jeffrey, S. C., Nguyen, M. T., Andreyka, J. B., Meyer, D. L., Doronina, S. O., and Senter, P. D. (2006) Dipeptide-based highly potent doxorubicin antibody conjugates. Bioorg. Med. Chem. Lett. 16, 358-62.
12. Jeffrey, S. C., Nguyen, M. T., Moser, R. F., Meyer, D. L., Miyamoto, J. B., and Senter, P. D. (2007) Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker. Bioorg. Med. Chem. Lett. 17, 2278-80.
13. Law, C. L., Gordon, K. A., Toki, B. E., Yamane, A. K., Hering, M. A., Cerveny, C. G., Petroziello, J. M., Ryan, M. C., Smith, L., Simon, R., Sauter, G., Oflazoglu, E., Doronina, S. O., Meyer, D. L., Francisco, J. A., Carter, P., Senter, P. D., Copland, J. A., Wood, C. G., and Wahl, A. F. (2006) Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res. 66, 2328-37.
14. Sun, M. M., Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y., Handley, F. G., Ihle, N. C., Senter, P. D., and Alley, S. C. (2005) Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjugate Chem. 16, 1282-90.
15. Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., and Senter, P. D. (2008) Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjugate Chem. 19, 759-65.
16. Shnyder, S. D., Cooper, P. A., Millington, N. J., Pettit, G. R., and Bibby, M. C. (2007) Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models. Int. J. Oncol. 31, 353-60.
17. Dubowchik, G. M., and Firestone, R. A. (1998) Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg. Med. Chem. Lett. 8, 3341-6.
18. Dubowchik, G. M., Mosure, K., Knipe, J. O., and Firestone, R. A. (1998) Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg. Med. Chem. Lett. 8, 3347-52.
19. Dubowchik, G. M., and Walker, M. A. (1999) Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol. Ther. 83, 67-123.